Nuformix (NFX) files first patent for novel cannabinoid cocrystals
The patent comes after the start of development activities as part of the Strategic Cannabinoid Agreement with Ebers Tech Inc.
The patented cannabinoid forms have immediate applications in both pharmaceutical and consumer products worldwide, the company said.
The number of patents filed is one of several key performance indicators for the collaboration, which generate milestone payments for Nuformix, in addition to 20% of royalties.
Ebers has exclusive rights to technology Nuformix patents for the development of differentiated cannabinoid products.
Shares in Nuformix were trading 5% higher on Monday following the filing
Cannabinoid products continue to attract more scientific interest as its therapeutic promise becomes increasingly validated.
Nigel Little, Director of Ebers said: “From a strategic perspective, Nuformix's proven track-record in securing worldwide patent protection for improved drug forms provides Ebers with an opportunity to generate high-value IP, identified as a limitation within the emerging cannabinoid market.”
Ebers Tech Inc. is a private Canadian cannabinoid development company backed by leaders from the financial sector with connections to major vertically integrated US cannabinoid players.
Dr. Dan Gooding CEO of Nuformix said that the IP filing was the “first disclosable validation of the Ebers agreement”. He added that the patent filing creates a path to further income from Ebers, and that the company will inform the market as further patents are filed and milestone and royalties are paid.
Follow News & Updates from Nuformix here: